甲磺酸雷沙吉兰结构式
|
常用名 | 甲磺酸雷沙吉兰 | 英文名 | Rasagiline mesylate |
---|---|---|---|---|
CAS号 | 161735-79-1 | 分子量 | 267.344 | |
密度 | 1.05 g/cm3 | 沸点 | 305.5ºC at 760 mmHg | |
分子式 | C13H17NO3S | 熔点 | 155-158°C | |
MSDS | 中文版 美版 | 闪点 | 146.8ºC | |
符号 |
GHS07 |
信号词 | Warning |
甲磺酸雷沙吉兰用途Rasagiline甲磺酸盐是MAO-B抑制剂,可作用于原发性帕金森病。 |
中文名 | 甲磺酸雷沙吉兰 |
---|---|
英文名 | Rasagiline Mesylate |
中文别名 | 雷沙吉兰甲磺酸盐 | (R)-N-2-丙炔基-1-氢化茚胺甲磺酸盐 |
英文别名 | 更多 |
描述 | Rasagiline甲磺酸盐是MAO-B抑制剂,可作用于原发性帕金森病。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.05 g/cm3 |
---|---|
沸点 | 305.5ºC at 760 mmHg |
熔点 | 155-158°C |
分子式 | C13H17NO3S |
分子量 | 267.344 |
闪点 | 146.8ºC |
精确质量 | 267.092926 |
PSA | 74.78000 |
LogP | 2.87240 |
外观性状 | 白色粉末 |
蒸汽压 | 0.000816mmHg at 25°C |
储存条件 | -20°C Freezer |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:4 4.可旋转化学键数量:2 5.互变异构体数量:无 6.拓扑分子极性表面积74.8 7.重原子数量:18 8.表面电荷:0 9.复杂度:305 10.同位素原子数量:0 11.确定原子立构中心数量:1 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:2 |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H302 |
危害码 (欧洲) | Xi |
风险声明 (欧洲) | R36/37/38:Irritating to eyes, respiratory system and skin . |
安全声明 (欧洲) | S26-S37/39 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
海关编码 | 2921499090 |
海关编码 | 2921499090 |
---|---|
中文概述 | 2921499090 其他芳香单胺及衍生物及它们的盐. 增值税率:17.0% 退税率:9.0% 监管条件:无 最惠国关税:6.5% 普通关税:30.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Lancet 365(9463) , 947-54, (2005) Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease. This study in... |
|
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Clin. Neuropharmacol. 23(6) , 324-30, (2000) Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monoth... |
|
Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
Neuroreport 9(4) , 703-7, (1998) Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been prime... |
acide méthanesulfonique - (1R)-N-prop-2-yn-1-yl-2,3-dihydro-1H-indén-1-amine (1:1) |
Methansulfonsäure--(1R)-N-prop-2-in-1-yl-2,3-dihydro-1H-inden-1-amin(1:1) |
methanesulfonic acid,(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine |
(1R)-N-(Prop-2-yn-1-yl)indan-1-amine methanesulfonate (1:1) |
(1R)-N-(2-Propyn-1-yl)-1-indanamine methanesulfonate (1:1) |
(1R)-N-prop-2-yn-1-yl-2,3-dihydro-1H-inden-1-amine methanesulfonate |
Rasagiline mesylate |
(R)-N-(Prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine methanesulfonate |
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine methanesulfonate (1:1) |
1H-Inden-1-amine, 2,3-dihydro-N-2-propyn-1-yl-, (1R)-, methanesulfonate (1:1) |
1H-inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate (1:1) |
Rasagiline (mesylate) |